

INDEX

ADDICTION

central nervous system, 340
conditioning of smoking habit, 78-79,
340, 342
development of smoking habit, 333-334
health warnings, recommendations, 486
historical perspective, 329-330, 340-342
National Institute on Drug Abuse, re-
search programs, 399
nicotine, psychosocial and pharmacologic
forces, 331, 334, 340, 342
public beliefs about tobacco use, 200, 216
relationship to price elasticity, 537
withdrawal symptoms, 343-344

ADOLESCENTS

access to tobacco, 235, 238, 596-604, 606
advertising effects, 339, 503-504, 660
behavioral risk factors compared with
smoking, beliefs, 215
beliefs about smoking, 212-215, 216,
222-223
cessation attempts, British and American
teenagers, 596
cigarette consumption, 660
developmental stage models, peer pres-
sure and coping patterns, 386
drug and alcohol use vs. smoking, beliefs,
214, 215
free tobacco product samples, 597
High School Seniors Surveys, 302-303,
306
initiation of smoking, 215, 296-297, 333-
335, 537-539
knowledge about smoking and smokeless
tobacco use, 217, 221, 222-223
parental and peer influences, 336-338,
389, 390
perceptions about smokers their own age,
227-229
prevention of smoking, programs, 394-
396, 398, 407-408
price elasticity of demand for cigarettes,
536-539
psychosocial curricula, 385, 389, 390

smokeless tobacco and oral neoplasm
risk, 217, 218
smoking cessation programs, 392-393
social trends and smoking prevalence, 409
Surgeon General's Reports, smoking
prevention, 400-401

ADULT USE OF TOBACCO SURVEYS (AUTSs)

airplane smoking restrictions, 573
employee smoke exposure after restric-
tion implementation, 594
cigar and pipe smoking, 322, 326-328
methodology and scope, 246-247
public service announcements, 497
smokeless tobacco use, 319-321
smoking continuum of quitting process,
286, 288-289, 292
smoking prevalence, 266, 271-272
tar yields of cigarettes, 315
tobacco use, 359
workplace smoking policies, prevalence,
582

ADVERTISING

(See also **PROMOTION**)
broadcast bans, 511, 514, 660-661
Cigarette Advertising Code, 511
consumption effects, 501-503, 514, 660-
661
decreased motivation to stop smoking,
502
disincentives, 516
expenditures, 499-500, 503, 507, 514,
661
Fairness Doctrine, application to ciga-
rettes, 414-415
Federal Trade Commission action against
R.J. Reynolds, 512
Federal Trade Commission guidelines for
evaluation, 510-511
guidelines, cigarette smoke constituents,
488-490
health warnings, 476, 479, 483-484
imagery and content regulation,
proposals, 515

initiation of smoking, 501
legibility of advertisements, 483-484
low-tar and -nicotine cigarettes, 665
market maturity and segmentation,
strategy, 506
preemption of State and local restrictions,
512
public health impact, 501
public transit bans, 513, 514-515
recall by children, effect on smoking be-
havior, 505-506
recidivism, 502
regulation of health claims by cigarette
manufacturers, 510
restrictions or prohibition, 178, 239-240,
515-516
revenues, media coverage, 508-510
stadium ban, Minneapolis, 513
teenager targets, 338-339, 503-504
tobacco industry questions about harmful-
ness of smoking, 511-512

ADVOCACY

American Lung Association, 417, 442
attempts to shift public perceptions, 436-
437
Coalition on Smoking OR Health, 439,
440, 443
Comprehensive Smoking Education Act
of 1984, 437
educational and behavioral programs,
policy initiatives, 383
Fairness Doctrine, antismoking lobbying,
441-442
National Commission on Smoking and
Public Policy, 443
National Interagency Council on Smok-
ing and Health, 437-438
nonsmokers' rights movement, 415, 442-
443, 558
objectives, 437-439
organizational characteristics of smoking
control groups, 432-440
State and local antismoking lobbying, 444
Tobacco-Free America Project, 383

AGE FACTORS

adult smokers and ex-smokers at risk,
134-137
Alameda County Study, mortality, 41
antismoking campaign effects among
birth cohorts, 651-657
cigar and pipe smoking, 327-328
coronary mortality, sex ratio, 144-145
initiation of smoking, 296-300, 537-539
lung cancer mortality, sex ratio, 143-144

mortality postponed or avoided, 667, 668,
669
smokeless tobacco use, males, 322-324
smoking continuum, 289, 291, 292
statistical analysis and relative risk,
women, 127
tar yields or menthol cigarettes, 316

ANTISMOKING CAMPAIGNS

American Cancer Society, 414
American College of Chest Physicians,
419-420
American Heart Association, 414
American Medical Association, 418-420
Coalition on Smoking OR Health, 418
Department of Defense, 425-427, 575
Doctors Ought to Care, 419
Fairness Doctrine, application to cigarette
advertising, 414-415
Federal Government efforts, 396-401,
649-657
funding sources, 516
Great American Smokeout day, 416-417,
426
Health Objectives for the Nation, 16-19,
433
health professional associations, 418-420
mass-media-based programs, 384-385
mortality postponed or avoided, 666-669
National Cancer Institute, 398-399, 421-
423
National Heart, Lung, and Blood In-
stitute, 399, 423-425
National Institute for Child Health and
Human Development, 399-400
National Interagency Council on Smok-
ing and Health, 395-396, 437-438
national voluntary health organizations,
394-395, 417-418
nationwide, net health consequences,
665-669
nonsmokers' rights movement, 442-433
Office of Disease Prevention and Health
Promotion, 425
Office on Smoking and Health, 397-398,
421
organizational characteristics of advocacy
groups, 439-440
State health departments, 427
Surgeon General's Reports, 400-401

ANTISMOKING MATERIALS

American Academy of Family
Physicians, 420
American Cancer Society, 395
American Heart Association, 394-395

American Lung Association, 394, 414
American Society of Internal Medicine,
420
National Cancer Institute programs, 421-
423

ARTERIOSCLEROSIS

aortic and coronary atherosclerosis, 60-61
claudication and aortic aneurysm mor-
tality, 65-66
peripheral vascular disease claudication,
63, 65

Asian Americans/Pacific Islanders

See **ETHNIC GROUPS**

ATTITUDES

(See also **ADULT USE OF TOBACCO
SURVEYS; CANCER PREVEN-
TION STUDIES; NATIONAL
HEALTH INTERVIEW SUR-
VEYS; SMOKING SURVEYS**)

addictive nature of tobacco use, 200, 202
adolescents, 212-215, 216, 217-218,
227-229, 409
air pollution, health risks, 207, 209-210,
211
alcohol consumption, health risks, 207-
212
asbestos exposure and smoking, lung
neoplasm risk, 202
ban on free samples, 239
blacks, risk factors for cardiovascular dis-
eases, 212
bladder neoplasms, smoking relationship,
195
broadcast antismoking messages, impact
on public opinion, 415
carbon monoxide in tobacco smoke, 217
cessation of smoking, health effects, 219,
220
children, harmfulness of smoking, *Weekly
Reader* survey, 215-216
chronic obstructive pulmonary disease,
smoking relationship, 188, 193-194,
195
consumption of cigarettes, health risks,
184
coronary heart disease, smoking relation-
ship, 188, 191-192
duration of smoking, health risks, 185,
186-187
smoking-and-health reports, effects on
public knowledge, 519
esophageal neoplasms, smoking relation-
ship, 195, 196

health effects of smoking, 179-181, 219,
221-222
heavy vs. light smoking, 181-184, 221
hiring of smokers, 241
inflight smoking bans, 573, 574
involuntary smoking, 200, 201, 224, 225
laryngeal neoplasms, smoking relation-
ship, 195, 196
life expectancy, risks of smoking, 206
low-yield cigarettes, health risks, 183,
185, 221
lung neoplasms, smoking relationship,
185, 186, 188, 189-190
neoplasms, smoking as risk factor, 212
nonsmokers rights, 224, 226
obesity, health risks, 207-212
oral contraceptives, interactions and risks,
197-199
peer influence on smoking, 336-338
pregnancy, dangers of smoking, 197
restrictions on smoking in public, 230-
239, 578
risk models, 206-212
smokeless tobacco use, mouth and throat
neoplasms, 202
smokers, personal risk, 202-204, 205
smoking-and-health advocacy groups, at-
tempts to change public perceptions,
436-437
survey methodology, 176-178
tobacco access laws, law enforcement of-
ficials, 605-606
types of cigarettes, harmfulness, 181
women, dangers of smoking, 195, 197-
199
workplace restrictions, 578, 589, 600-601

BEHAVIOR, HUMAN

actions of smokers among nonsmokers,
227
child risk taking, 399-400
estimated risks of various activities, 160
health risk knowledge vs. smoking habit,
344-345
self-efficacy and smoking cessation, 351
self-reported smoking status, 265-266
switching cigarette types, antismoking
campaign, 664-665

BIOASSAY

biochemical markers, mainstream and
sidestream smoke, 94-97
smoking status validation, vs. self reports,
265
thiocyanates and diet, 96

BIRTH DEFECTS

parental smoking, 73, 75
cessation of smoking, 73
fetal hypoxia and carbon monoxide, 72
maternal smoking, dose-response effect, 72

BLACK AMERICANS

adolescents, smoking prevalence, 303-306
cardiovascular disease risk, beliefs, 212
initiation of smoking, 301-302
maternal smoking, 72, 73-74, 275
prevalence of smoking, 269-271
quit ratios, gender, 286
self-reported daily cigarette consumption, heavy smokers, 295
statistical bias, lung cancer risk among women, 129
tar and nicotine content, beliefs about health risks, 183, 185

CALIFORNIA

nonsmokers' rights group, proposition on smoking restrictions, 442
public transit bans, 513, 574
restaurant smoking restrictions, Beverly Hills, 571
Safe Drinking Water and Toxic Substances Enforcement Act, 612
San Diego study, National Clearinghouse for Smoking and Health, 397
warning labels, tobacco products, 612
workplace smoking restrictions, 570-571, 577

CANADA

ban on tobacco advertising and promotion, 516
public beliefs about addictive nature of tobacco use, 200, 202
Tobacco Products Control Act, 487
transportation smoking restrictions, 574, 588-589

CANCER PREVENTION STUDIES

(AMERICAN CANCER SOCIETY)
chronic obstructive pulmonary disease and smoker mortality, 146
comparability with other studies, 140-141
coronary heart disease and smoker mortality, 144-145
estimated relative risks, cancer, coronary and pulmonary diseases, 146-152
lung cancer and smoker mortality, 143-144

mortality, 122, 142
relative risk changes, 131-132
sampling bias and validity, 128-129

CARBON MONOXIDE

advertising guidelines, 488-489
carboxyhemoglobin, biochemical markers, 96
public beliefs about tobacco smoke constituents, 217

CARCINOGENESIS

adenomas, adenocarcinomas, and carcinomas, long-term smoke exposure, 93
polynuclear aromatic hydrocarbons and N-heterocyclic hydrocarbons, 85
tumorigenic agents in tobacco, 86-87
reduction by tobacco additives, 614

CEREBROVASCULAR DISORDERS

drug therapy efficacy, 63
estimated relative risks, 1960s and 1980s 147-152
Japanese-American men, Hawaii, 62
mortality and morbidity, 61-62
public beliefs about smoking and oral contraceptive use, 197, 198
risk factors, 61-62, 63
women and smoking habit, 62-63

CESSATION OF SMOKING

adolescent attempts, Britain and United States, 596
advertising and promotion of tobacco, effects, 502
brand-switching as alternative, health consequences, 665-666
cardiovascular disease risk reduction, 423-424
cerebrovascular disease risk reduction, 147, 152
ethnic and demographic differences, 286-287
expectancy-value and health-belief decisionmaking models, 350-351
gender differences, 354
historical perspectives, 330, 434-436
hospital restrictions, impact, 589, 592
immediate vs. long-term effects of tobacco, 393
indicators of quitting activity, 285
insurance, 551-552, 552-553
lung cancer risk reduction, 55, 127
nicotine dependence, 349
outcome expectations, 352

pharmacologic processes and conditioning, 349
physician impact, 418-420
precontemplation, contemplation, and action stages, 348
pregnant women, 353, 400
public beliefs about health effects, 219, 220
reimbursement of drug treatment, 553
restrictions as incentive, 578-579
role of disease incidence, 352-353
self-efficacy model, 351-352
smoking continuum of quitting process, 288-289, 292
stage model, opportunities for older adolescents, 386
stages, 413
trends, 287
workplace policies, 354-355, 589, 563
workplace restrictions, impact, 592
young smokers, quit attempts, 392

CESSATION OF SMOKING, METHODS

acupuncture, 431
American Lung Association materials, 414
clonidine, 428
commercial programs, 427, 431-432
computer-assisted program, 431
filter systems, 430
Great American Smokeout day, 416-417
history of aids and treatments, 409-413
How to Quit Smoking workplace program, 432
how-to-quit materials, 430
hypnosis, 431
interpersonal support, 354-355
Live for Life workplace program, 432-433
lobeline sulfate capsules, 428
nicotine polacrilex gum, 428-429, 553, 616
nonpharmacologic aids, 430-431
pharmacist's antismoking materials, 425
pharmacologic cessation aids, 428-429
physician advice and materials, 418-419, 422-423
quit rates for different treatments, 410-413
Schick Stop Smoking program, 432
silver acetate, 428
Smoke Stoppers program, 433
smokeless cigarettes, 430
Smokeless program, 433
SmokEnders program, 431

CHILDREN

access to tobacco, 596-597, 599-603, 603-604
beliefs about harmfulness of smoking, *Weekly Reader* survey, 215-216
intervention approaches for young smokers, 386
maternal smoking, long-term effects, neurological handicaps, 75-76
parental smoking effects, 336-338
penalties for tobacco possession, 603
psychosocial approaches to antismoking education, 385
recall of cigarette advertisements, effect on smoking behavior, 505-506
revenue from tobacco sales to minors, 605
States prohibiting free tobacco samples for minors, 599-602
Surgeon General's Reports, smoking prevention, 400-401

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

age-specific death rates, 146
attributable risks, sex ratio, 153-161
morbidity and mortality, 66-67, 71, 141-142
pathogenesis, enzyme activity, 67
pathophysiology, emphysema and small-airway injury, 67-68
public beliefs about smoking relationship, 188, 193-194, 195
respiratory function tests, 68-70
ventilatory function, 68-71

CIGAR SMOKING

age-adjusted relative risks, 153
gender, age, race, socioeconomic and demographic factors, 322, 326-328
lung cancer mortality, 50
mortality, vs. pipes vs. cigarettes, 41-42
prevalence rates, men, 134

CIGARETTES, LOW-NICOTINE

alternative to cessation, antismoking campaign, 664-665
lung cancer mortality, 44, 46
public beliefs about health risks, 183, 185
yield, sales, consumption, 313-314

CIGARETTES, LOW-TAR

alternative to cessation, antismoking campaign, 664-665
changes in tobacco products, risk assessment, 139
lung cancer mortality, 44, 46

public beliefs about health risks, 183, 185, 221
safety and public perceptions, 416
yield, sales, consumption, 313-315

CIGARETTES, LOW-YIELD

alternative to cessation, antismoking campaign, 664-665
consumption, 658
health effects, 315-316, 666
market share, 665
public health concerns, 183, 185, 490
safety and public perceptions, 416
tar and nicotine reductions in filtered products, 85, 88

COGNITION

developmental model of smoking acquisition and prevention, 391-392
health effects of smoking, knowledge, 335-336, 344-345
Health Objectives for the Nation, 1990, public knowledge, 223-224
health warnings, effectiveness of wording and format, 484
risk assessment, understanding by public, 222
smoking cessation, 348-349, 350-351, 351-352, 353

COLORADO

Aspen, smoking ordinances, effects on business, 572

CONDITIONING

biological effects of nicotine, 343
environmental smoking cues, 349-350
pharmacologic effects of nicotine in smoking cessation, 349
withdrawal symptom relief, 343-344

CORONARY HEART DISEASE

age-specific death rates, 144-145
attributable risks, 153-161
avoidable risk from smoking, 131
Cancer Prevention Studies, risk factors and potential bias, 128
changes in risk behavior, with smoking, 139-140
diabetes as risk factor, 59
estimated relative risks, 147-151
myocardial infarct risk, mortality and treatment, 58-59, 61
nonsmoker mortality, 141-142
pathophysiologic mechanisms, 60-61
public beliefs about smoking relationship, 188, 191-192

risk factors and smoking, 59-60
smoking cessation effects, 61
survey of patients' siblings on risk factors, smoking, 212

DEMOGRAPHIC FACTORS

bias in risk assessments, 128
cigar and pipe smoking, 327-328
education, 269, 271, 286, 287, 289-290, 292, 301-302, 303-306, 316
gender, 276, 322-326
gender, socioeconomic, and personality variables, smoking habit, 329
personal characteristics and smoking, 347
region, gender, education, and smoking prevalence, 279, 282-283
smoking cessation and relapse, 353
variation among antismoking strategies, 408-409

DIET

cholesterol, 207, 209-210, 212
hypercholesterolemia, 139-140
lung cancer and protective effects of vitamins, 54

DRUG ABUSE

adolescent beliefs, smoking vs. other substance use, 214, 215
cigarettes as a "gateway drug," 399
integration of smoking prevention programs into substance abuse programs, 401
marijuana smoking, public beliefs, 207, 211
school health education programs, 388-389

ECONOMICS

ban on cigarette sales, public opinion, 235, 237
cigarette prices in military commissaries, 426
consumer demand and production factors, 660-661
institutional dependence on tobacco industry, effect on consumption, 502
price elasticity, 533-538, 662-664
public service announcements, effects on cigarette consumption, 498
public transit advertising ban, impact, 514-515
restaurant smoking ban, effect on business, Aspen, 572
trends in per capita cigarette consumption, 267-268

Education

See **DEMOGRAPHIC FACTORS;
HEALTH EDUCATION**

EMPHYSEMA

airflow obstruction, 67-68
morbidity and mortality, chronic obstructive lung disease, 66-68
protease-antiprotease activities in pathogenesis, 67
public beliefs about smoking relationship, 188, 193-194, 195

Environmental tobacco smoke

See **INVOLUNTARY SMOKING**

ETHNIC GROUPS

(See also **BLACK AMERICANS**)

Asian Americans, Hawaii, smoking prevalence, 275
cigar and pipe smoking, 327-328
Hispanics, smoking prevalence, 274
Native Americans and Alaskan Natives, smoking prevalence, 274
race and smoking continuum, 289, 291, 292
racial differences in smoking onset and prevalence, 338
smokeless tobacco use, 322-324
tar yields and menthol cigarettes, 316

EX-SMOKERS

age factors, 136
attributable risk, lung cancer, and women, 127
health benefits of smoking cessation, 666, 667
lung cancer risk reduction, 55
measurement of quitting activity, 285
mortality, sex ratio, 147-152
prevalence, 132-134, 288-289
public beliefs about risk reduction after smoking cessation, 219, 220
self-attained cessation of smoking, 413

FILTERS

lung cancer mortality, 44, 46
reduction of toxic and tumorigenic agents in cigarettes, 85
sales, consumption, 313-314
shift from unfiltered, antismoking campaign, 664-665
use, lower yield cigarettes, 138-139

FIRES

fire-safe cigarettes, development and feasibility, 614

insurance, smoking-related deaths and damage, 550
smoking-related deaths, 614

Former smokers

See **EX-SMOKERS**

HEALTH EDUCATION

advocacy group activities, 438
budgets of Federal agencies, 520-523
Comprehensive Smokeless Tobacco Health Education Act, 478, 481, 490, 511, 512, 518
Comprehensive Smoking Education Act, 478, 479, 481, 490, 512, 517-518
Department of Defense, 426, 521
integration of programs with policy initiatives, 383
national goals, 16-19
National Heart, Lung, and Blood Institute, Smoking Education Program, 424-425
national voluntary health organizations, 394-395, 413-418
prevention of smoking programs, 335-336, 385, 397-398, 401-402, 403-405, 406, 407-408
school-based programs, 388-389, 390, 391, 491-494
Surgeon General's Reports, smoking prevention, 401
teacher training, State requirements, 494, 495
youth programs, cessation of smoking, 392-393

Hispanic Americans

See **ETHNIC GROUPS**

INDIANA

designated smoking areas in hospitals, 586

Inhalation patterns

See **SMOKING CHARACTERISTICS**

INITIATION OF SMOKING

advertising and promotion of tobacco, 501
age, adults vs. adolescents, 296
campaign-related decreases, 666-667
delay, smoking prevention programs, 406
developmental stages models, 385-386
knowledge of health effects, 335-336
lung cancer mortality, men, 45
National Institute for Child Health and Human Development, 399-400
peer pressure, 389-390

pharmacologic processes and conditioning, 333-335
prevalence of smoking, 135-136, 137
price effects, 537-538
risk personalization, 215
social influence and life skills training approaches, 390-391
trends, gender, race, and education, 301

INSURANCE

auto, 550-551
biochemical validation of smoking status, life insurance, 545
coverage of smoking cessation treatment, 552-553, 557
nonsmoker premium discounts, 543, 544, 546-551
premium calculations, smoking status, health maintenance organizations, 548
premium differentials, incentives to stop smoking, 551-552

INVOLUNTARY SMOKING

biochemical markers, 95-97
exposure risks, lung cancer, nonsmoking women, 77-78
Federal workplace policy to limit exposure, 575
indoor air pollution, lung cancer risk, 53-54
nonsmokers' rights movement, 442-443
public annoyance, survey results, 224, 225
public beliefs about risk, 200, 201
regulation of environmental tobacco smoke, 613
sidestream effects, toxic and tumorigenic agents, 88-91
workplace exposure, restriction rationales, 580-581, 594

LABELING

Federal Cigarette Labeling and Advertising Act of 1965, 7, 475-476, 477, 482, 518, 519
Federal Trade Commission requirements, 475-476
health warnings, 479-482, 484-487, 612
nicotine polacrilex gum package inserts, 482
oral contraceptives, 481-482
oral snuff warning labels, Massachusetts, 612
Palmer v. Liggett, 612
public opinion, 241, 242

LEGISLATION

(See also **TAXATION**)

Cigarette Labeling and Advertising Act, 441
Cigarette Safety Act, 614
Clean Indoor Air Acts, 558, 572, 613
Comprehensive Smokeless Tobacco Health Education Act, 443, 478, 481, 490, 511, 512, 518, 612
Comprehensive Smoking Education Act, 398, 437, 443, 478, 479, 481, 490, 512, 517-518
Consolidated Omnibus Budget Reconciliation Act, 443
Consumer Product Safety Act, 611
Controlled Substances Act, 610-611
Federal Cigarette Contraband Act, 534
Federal Cigarette Labeling and Advertising Act of 1965, 7, 19, 137, 475-476, 482, 517, 518
Federal Food, Drug, and Cosmetic Act, 609
Federal Hazardous Substance Labeling Act, 610, 611
Food and Drugs Act of 1906, 608-609
Little Cigar Act, 477, 486, 511
Minnesota Clean Indoor Air Act, 558
Occupational Safety and Health Act, 612-613
Omnibus Budget Reconciliation Act, 528
Public Health Cigarette Smoking Act, 441, 476, 477, 496 511 512, 517, 518, 520
Public Health Service Act, 613
Safe Drinking Water and Toxic Substances Enforcement Act, 612
tobacco access laws, 597-598, 606, 607-608
Tobacco Products Control Act, Canada, 487
Toxic Substances Control Act, 611

LITIGATION

Action on Smoking and Health v. Harris, 611
American Public Health Association v. Consumer Product Safety Commission, 611
Austin v. Tennessee, 598
Cippollone v. Liggett, 611-612
Federal Trade Commission v. Brown and Williamson, 489, 511
Federal Trade Commission v. Liggett and Myers, 608-609

Federal Trade Commission v. R.J. Reynolds, 512
Illinois Cigarette Service Co. v. City of Chicago, 598
Mutual Benefit Life Insurance Company v. JMR Electronics Corp., 545-546
Palmer v. Liggett, 612
Parker v. City School Superintendent, 606
U.S.A. v. Liggett, 476
U.S.A. v. R.J. Reynolds, 476

Lobbying

See **ADVOCACY**

LUNG NEOPLASMS

age-specific mortality rates, 143-144
asbestos exposure, smoking and risk, 202
dose-response relationships, 43-46
familial determinants, 52
female mortality, 46-49, 125-126
histologic type, 50-51
inhaled tobacco carcinogens, 93
International Classification of Diseases, 130
male mortality, 44-45
nonsmoker mortality, 141-142
public beliefs, smoking and risk, 185, 186, 188, 189-190, 202
radon and risk, 53-54
vitamins, protective effects, 54

MASS MEDIA

advertising restrictions, 239-240
advertising revenues, 502, 508-510
American Cancer Society, television advertisements, smoking cessation, 414
American Lung Association, series for news broadcasts, 417-418
broadcast ban of tobacco advertisements, 496, 511
Cigarette Advertising Code, 511
coverage of smoking and health related to cigarette advertisers, 509
national voluntary health organizations, television campaigns, 415-416
news media coverage of health risks, 222
public service announcements, 497-500
video news releases, 388

MASSACHUSETTS

availability of tobacco to adolescents, 604-605
Cambridge, smoking restrictions, 577
local smoking ordinances, prevalence, 572
oral snuff, warning labels, 612

public opinion about smoking restrictions, 578
public transit advertising ban, 513

MATERNAL SMOKING

birth defects, dose-response, 72
blacks, 72, 73-74, 275
demographic factors, 275-276
fetal and perinatal mortality, 73
hypoxia, fetal and neonatal effects, 72
infant birthweight, 72-73
infant mortality, 73-74
long-term effects, 75-76
National Institute for Child Health and Development, 400
neurological handicaps, 75-76
public beliefs about smoking effects, 195, 197, 221
socioeconomic status, 276
spontaneous abortion and chromosomal abnormalities, 73

MATHEMATICAL MODELS

attributable risks from cigarette smoking, 153-161
attributable, relative, and absolute risks, hazardous exposure variables, 123-125
avoidable deaths from cancer and coronary heart disease, 131
consumption patterns, changes in smoking-and-health environment, 662-664
dose-response relationships, 44
lung cancer rates among females, 125-126
mortality postponed or avoided, 666-669
smoking prevalence, 270, 651-657
synergy of radon exposure and cigarette smoking, 125

MINNESOTA

Clean Indoor Air Act, 558
excise funding of smoking prevention program, 402
hospital smoking ban, 586
smoking control program, 524, 542
stadium advertising ban, 573

MORTALITY

(See also **MATHEMATICAL MODELS**)

age factors, 41-42, 45
all and specific causes, smokers and ex-smokers, 146-152
attributable risks from smoking, 130-132, 154-156, 206-207
cancer, 47, 48

cardiovascular and respiratory disease, cancer, 39-40
diabetes and coronary heart disease, 59
esophageal neoplasms, 56
laryngeal neoplasms, 56
misclassification of cause, International Classification of Diseases, 130
oral neoplasms, 56
overall rates, 38-41
pancreatic neoplasms, 56-57
postponed deaths, campaign-induced, 666-669
public beliefs about risks, 206
relative risk, lung cancer, women, 126
smoker vs. nonsmoker, 544-545
smoking-attributable total, 160
statistical bias, lung cancer risk among women, 129
stomach neoplasms, 57
stroke, 61-62, 64
tax-related changes, 540

MULTIPLE RISK FACTOR INTERVENTION TRIAL (MRFIT)

advertising by R.J. Reynolds, misrepresentation of study, 512
mortality and morbidity, smoking habit, 41
program history, National Heart, Lung, and Blood Institute, 423-424

NATIONAL HEALTH INTERVIEW SURVEYS (NHISs)

daily cigarette consumption, 292-293, 295
gender, race, education, 267, 269-270
initiation of smoking, 297, 301
methodology and scope, 250-251
population-weighted mortality data, 122
prevalence data, self-respondents and proxies, 132-133
quit ratios, 286, 287
sampling errors, 129
smokeless tobacco use, 319-320
smoking prevalence, 272-274, 298, 299

Native Americans or Alaska Natives

See **ETHNIC GROUPS**

NEOPLASMS

attributable risks, sex ratio, 1965 and 1985, 153-161
avoidable risk from smoking, 131-132
bladder and kidney, smoking dose-response, 56
public beliefs about smoking risk, 212

NEW YORK

Clean Indoor Air Act, 572
commuter rail smoking ban, 573
compliance with restaurant smoking restrictions, 577
public opinion about smoking restrictions, 577-578
workplace smoking policies, 582

NICOTINE

advertising guidelines, 488-489
alkaloids in tobacco, 79
biochemical marker, 95-97
conditioning and smoking, neurohumoral effects, 343
deposition, absorption, and metabolism, 93-94
historic perspective, smoking behavior, 329-330
metabolism, 94-96
peptic ulcer, 76
proposed Federal regulation of cigarette content, 610
regulation of blood level, 342
trend for cigarette content, 88

NICOTINE DELIVERY

alternative products, 615-616
nicotine aerosols, 616
nicotine polacrilex gum, 616
reduced-smoke cigarettes, 617
smokeless cigarettes, 318-319
tobacco chewing gum, 616
tobacco toothpaste, 616

Nicotine polacrilex gum

See **NICOTINE DELIVERY; CESSATION OF SMOKING, METHODS**

NONSMOKERS

beliefs about personal risks of smoking, 203, 204
health claims, 549
insurance premium discounts, 546-548
lung disease, involuntary smoking, 77-78
mortality rates, 141-145
prevalence, 288-289
workplace smoking restriction, 575, 584, 590, 591

Nonsmokers' rights

See **ADVOCACY**

OCCUPATIONAL DISEASES

asbestos exposure, public beliefs about smoking risks, 202

workplace exposures, lung cancer risk, 52-53, 128

OCCUPATIONS

blue-collar workers, 272-274
industry type, 585
managers, 585
military personnel, 277-278, 347, 425-427
white-collar workers, 272

Passive smoking

See **INVOLUNTARY SMOKING**

PEER GROUPS

initiation and maintenance of smoking, 336-338
smokers vs. abstainers, 355
social support, smoking, and cessation, 354-355

PERCEPTION

health risks of smoking, health warnings, 485
positively perceived effects of smoking, 342
social acceptability of smoking, 347

PERSONALITY

extraversion, 336, 345
internal vs. external locus-of-control dimension, 346
marketing campaigns and personality characteristics, 339
negative affect smoking, 346
neuroticism, delinquency, and smoking status, 336
psychosocial factors, smoking habit, 329
relapse rates after smoking cessation, 353

PIPE SMOKING

age-adjusted relative risks, 153
lung cancer mortality, 50
mortality, vs. cigars and cigarettes, 41-42
prevalence among men, 134
socioeconomic and demographic factors, 322, 326-328

PREVENTION OF SMOKING, PROGRAMS

American College of Chest Physicians, 419-420
American Nonsmokers' Rights Foundation, 402
American Pharmaceutical Association, 423
construct validity, 406-407

demographic and historic factors, 408-409

Department of Defense, 425-427
design and target audiences, trends, 384
dissemination, 403-405
evaluation, 405
Federal Government support, agencies and reports, 396-401
Federal guides of existing resources, 396
general school health education levels, 389
Great American Smokeout day, 416-417
health professional organizations, 402-403
historic perspective, 330
long-term followup, 406
mass media, 387-388
National Cancer Institute, 398-399, 421-423
National Heart, Lung, and Blood Institute, 399, 423-425
National Institute on Drug Abuse, 399
National Interagency Council on Smoking and Health, 395-396
Office of Disease Prevention and Health Promotion, 400, 425
Office on Smoking and Health, 397-398, 421
psychosocial curricula, 389-392
school health education, 388-389
State, 401-402, 427
voluntary health organizations, 394-395, 407-418
workplace, 425, 432-434
youth, 392-393

POLICIES

advertising imagery and content, proposals, 515
categorization of tobacco control efforts, 472, 473
educational and behavioral interventions and initiatives, 383
Fairness Doctrine, 441-412, 496, 660-661
Health Objectives for the Nation, 16-19, 223-224
history of smoking-and-health research and regulation, 5-6
national goals for insurance, nonsmoker premiums and actuarial data, 553-555
restriction of advertising and promotion, 515-516
restriction of smoking, impact on per capita consumption, 661-662

taxonomy of workplace smoking policies, 581
trends, 409-413
warning labels, Federal Trade Commission requirements, 475-476

PROMOTION

(See also **ADVERTISING**)

decreased motivation to stop smoking, 502
encouragement of smoking initiation, 501
encouragement of recidivism, 502
expenditures, 499-500
free distribution of tobacco products, 239, 513, 514, 597, 603-604
nicotine polacrilex gum, 429
proposed restrictions, 515
States prohibiting tobacco sales to minors, 599-602
tobacco consumption, 501-502

Public service announcements

See **ADVERTISING; ADVOCACY; HEALTH EDUCATION; SMOKING CONTROL PROGRAMS**

RECIDIVISM

advertising and promotion of tobacco, 502
body weight and smoking cessation, 354
coping responses, 350
gender differences, 354
prevention strategies, 410, 413
socioeconomic and demographic factors, 353
stress, negative affect, 349
triggers to relapse, 349-350

RESTRICTION OF SMOKING

airplanes, 232, 573-574, 588-589
airports, 574
Clean Indoor Air Act, New York, 572
consumption impact, 591-592, 661-662
Department of Defense, 575
economic impact, 594-595
educational institutions, 561-568, 587-588
Federal Government workplaces, 574-575
fire hazards, 557
health care facilities, 561-568, 585-586, 561-562
industry type and prevalence of smoking policy, 585
local ordinances, 570-572, 577
penalties for noncompliance, 561-568
pharmacies, 587

physician offices and medical organizations, 586
provisions of laws, 560, 568
public places, 232-233, 556-557, 558
public transportation, 561-568, 573, 574
regional variation, 570, 571
restaurants and hotels, 235, 236, 569, 570, 577
State laws, 558-560, 561-569, 569-570, 599-602
target occupational groups, 595
tobacco access laws, 603, 604-606, 607-608
trends in public beliefs, 230-231
vending machines, access, 603-604
workplace policies, 232, 561-568, 600-601, 577, 581-585, 590, 591, 593, 594-595

SEX RATIO

age-specific death rates, 144-145, 146
antismoking campaign effects, 650-657
attributable risks for cancers, coronary and pulmonary diseases, 154-156
initiation of smoking, 296-300
lung cancer mortality, 46
mortality postponed or avoided, 667, 668-669
nonsmoker mortality, 141-142
self-reported daily cigarette consumption, 295
smokeless tobacco use, 320-322
smoking cessation and relapse, 354
smoking continuum, 289-290
smoking prevalence, 132-133, 134-135, 136-137, 138, 269-270, 272, 279, 282-283, 298, 301, 302, 303-305, 307-312, 316

SMOKE STREAMS

mainstream chemical analysis, vapor and particulate phases, 79-85
sidestream effects, toxic and tumorigenic agents, cigarettes, 88-91

SMOKELESS TOBACCO

advertising strategy, graduated use, 507
antismoking pamphlet, American Dental Association, 420
Comprehensive Smokeless Tobacco Health Education Act, 478, 481, 490, 511, 512, 518
disclosure of nicotine content, requirements, 500
Federal excise tax, 528

health warning requirements, 478, 479, 480, 481
nitrosamine formation and oral cancer, 90, 92
snuff-dipping and oral cancer, leukoplakia, 78
State excise taxes, 529

SMOKELESS TOBACCO USE

adolescents, 217, 393
National Cancer Institute prevention programs, 398
prevalence among males, 319-322, 325-326, 657
public beliefs, mouth and throat neoplasms, 202

SMOKING BEHAVIOR

adults, 134-135, 140, 298, 302
advertising effects, 501-502, 506-507
appetitive model, smoking cues, 344
Asian Americans, 275
chronic obstructive pulmonary disease, 68-69
cigarette consumption, 267-268, 293-294, 518-519, 592, 657-662
determinants of smoking, stages, 334
development, maintenance, cessation, 331-332, 334
estimated prevalence in absence of anti-smoking campaign, 651-657
gender, race, education, 269-270, 302-306
heavy vs. light smoking, 181-184, 221
Hispanics, 274
intensity, biochemical markers, 95-97
maintenance, pharmacologic processes and conditioning, 340, 342
men, 269-270
military personnel, 276-278, 575
Native Americans, 274
nicotine dependence, 331, 349
opponent-process theory, aversive withdrawal symptoms, 343-344
oral contraceptive use, 140
personal characteristics, 336, 345-347
pregnant women, 275-276
price elasticity and smoking prevalence, 536-539
public beliefs about duration and health risks, 185, 186-187
public service announcements, 497-500, 514
self-reported status vs. biochemical validation, 265

socioeconomic and demographic factors, 329
State legislative impact, 578-579
State-specific prevalence, 280-281
Third World countries, 19
workplace policies, 584, 589, 591-592

SMOKING CHARACTERISTICS

compensation, 316, 317
inhalation patterns and lung cancer mortality, 45
length of cigarette, market share, 317-318
menthol cigarettes, inhalation, 317
sex ratio, 132-133

SMOKING CONTROL PROGRAMS

hospital prohibition of cigarette sales, 586
knowledge among smokers about health effects, 221
Minnesota, 525, 542
Office on Smoking and Health, 397
Rocky Mountain Tobacco-Free Challenge, 524
tobacco taxes as funding source, 542-543
Utah, excise revenues, 542

SMOKING SURVEYS

(See also ADULT USE OF TOBACCO SURVEYS; CANCER PREVENTION STUDIES; NATIONAL HEALTH INTERVIEW SURVEYS)

American Medical Association, 247
Behavioral Risk Factor Surveillance System, 247-248, 278-279, 280-281
Chilton Survey, 1979, 248
Collaborative Perinatal Study, 276
Current Population Survey, 248, 279, 282-283, 322
Department of Defense, 276-278, 427
Gallup Surveys, 248-249
High School Seniors Surveys, 296, 302-303, 306
Hispanic Health and Nutrition Examination Survey, 251, 274
Lieberman Research, Inc., 249
methodology, public attitudes on health effects of smoking, 175-177
National Adolescent Student Health Surveys, 250, 296-297, 306-307
National Health and Nutrition Examination Surveys, 251
National Household Surveys on Drug Abuse, 312
National Institute on Drug Abuse High School Seniors Surveys on Drug Use, 251-252

National Maternal and Infant Health Survey, 275
National Natality Surveys, 275
National Survey of Family Growth, 276
Native Americans and Alaskan natives, 274
Roper surveys, 252-253
teenagers, 307-309, 310-312
U.S. Department of Health, Education, and Welfare Teenage Smoking Surveys, 253

SNUFF

ban on sales, 617-618
marketing and labeling, 615
warning labels, Massachusetts, 612

SNUFF-DIPPING

adolescents, beliefs about harmfulness, 217, 218
adults, 1964 to 1986, 319-322
males, 319-322
prevalence and proposed ban, 615

SOCIOECONOMIC STATUS

birthweight and maternal smoking, 73
blacks vs. whites, smoking prevalence, 269-270
cessation and relapse, 353
cigar and pipe. smoking, 328
educational level and occupation, 139
personal characteristics and smoking, 347
pregnant women, 276
smokeless tobacco use among males, 322-323
students with blue-collar backgrounds, 408

SOUTH CAROLINA

local smoking restrictions, 572

STATISTICAL ANALYSIS

(*See also* **MATHEMATICAL MODELS; SMOKING SURVEYS**)
adolescent smoking, weekly vs. daily rates, 307, 312
advertising expenditures and tobacco consumption, 504-505
age adjustment and relative risk, 127
aggregation vs. precision, lung cancer risk among women, 127
attributable risk, causation, and mortality, 122-123
bias in risk assessments, 128
Cancer Prevention Studies, age adjustment of relative risks, 141

data errors, exposures and causes of death, 129-130
data sources, 264
methodology of public opinion surveys, 175-178
per capita consumption studies, 657-658
risk factor interaction with smoking, 50-51
synergy and statistical bias, 128

STRESS

consumption and initiation, smoking habit, 329
public beliefs about risks of smoking, 207-210, 212
reduction, biological effects of nicotine, 346-347
smoking cessation and relapse, 353

STUDENTS

adolescents, personalization of smoking risks, 215
beliefs on health effects of smokeless tobacco, 217, 218
litigation, school smoking lounges, 606
parental awareness of school-based programs, 387
program failure to reach dropouts, 407-408
school health education curricula, 388-389
school smoking restrictions, 587-588

TAR CONTENT

advertising guidelines, 488-489
chemical analysis of particulate matter in mainstream smoke, 83-84
proposed Federal regulation of cigarettes, 610
reductions, 85, 88, 617
smokers' gender, age, race, education, 316

TAXATION

ad valorem tax on cigarettes, revenues, 542
cigarette price changes, 662
evasion of cigarette taxes, cigarette bootlegging, 531-533, 541
excise taxes, 264
Federal and State tobacco tax increase, effects, 541
Federal excise tax, 527-528, 529, 530, 540
Indiana, cigarette excise tax, 542
licensing requirement for tobacco sales, 604

Minnesota, cigarette excise tax, 402, 525
Nebraska, cigarette excise tax, 542
price elasticity of demand, 533-538
sales tax exemption, 541
smoking-related deaths, effects of tax rates, 540
State and local excise rates and prevalence, 528-532
tax-exempt cigarette sales, impact on States, 533
tobacco tax revenues for State smoking control programs, 542-543
unit tax on cigarettes, 542
Utah, cigarette excise tax, 542

TEXAS

smoke-free hospital rooms, 586
workplace smoking restrictions, 583

TOBACCO ADDITIVES

changes in cigarettes, 139
disclosure requirements, 490
menthol cigarettes, health effects, 317
pesticide traces, 82, 85
reduction of carcinogens, 614
risks and disclosure, 613

TOBACCO INDUSTRY

advertising refuting claims about harmfulness of smoking, 511-512
censorship of smoking and health items, 509-510
Cigarette Advertising Code, 511
code regarding free samples, 597
compliance with health warning legislation, 476, 483
disincentives to advertise, 516
lobbying efforts, 440-441
marketing of low-yield cigarettes, 665
restrictive policies, 595
vending machine sales, 604

TOBACCO SMOKE

physical chemistry, carcinogenic and mutagenic effects, 79-85
tar and neoplasms, 93
toxicity and carcinogenicity, 92-93

UTAH

public transit advertising ban, 513
smoking control program, 542

UTERINE NEOPLASMS

cervical cancer, smoking and other risk factors, 57-58
endometrial and cervical cancers, risk vs. protective factors, 152
endometrial cancer and estrogen levels, 58

VIRGINIA

local smoking restrictions, 572

WOMEN

all-cause and specific mortality, 146-147, 149, 151-152
attributable risk, cancers, cardiovascular and pulmonary diseases, 157-158
attributable risk, lung cancer, 126
cancer mortality risk, 47
cervical and endometrial cancer, 57-58
fertility and smoking, 75
initiation of smoking, 299, 300, 301, 302
lung cancer mortality risk, 46-49, 144
mortality postponed or avoided, smoking cessation or noninitiation, 667, 668-669
National Institute for Child Health and Human Development, cessation of smoking program, 400
oral contraceptive use, 140, 197-199, 481-482
osteoporosis, calcium intake, estrogen, and obesity, 76-77
pregnancy, dangers of smoking, public beliefs, 195, 197-199, 221
pregnancy, demographic factors, smoking prevalence, 275-276
pregnancy, smoking cessation programs, 418, 427
public beliefs about dangers of smoking, 195, 197-199
response to antismoking campaigns, 650-651, 653-657
smoking prevalence, 1965 to 1987, 269-270
stress, smoking cessation and relapse, 3 5 3 - 3 5 4
stroke and smoking habit, 62-63

U.S.G.P.O. 1989 623-880/10288